News & Events
Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Dec. 7, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients undergoing allogeneic hematopoietic cell…
Genetic Analysis announces terms of the previously announced subsequent offering to shareholders of up to appr. NOK 9 million (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…
Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Nov. 28, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 , at 3:30 p.m. ET .…
Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings (opens in a new tab)
The three patents broadly cover therapeutic compositions of clostridial bacteria derived from the human microbiome and their uses in infectious disease, allergy, and autoimmune disease Vedanta’s claims were maintained as granted in all three cases Decision further solidifies Vedanta’s leading IP position in the maturin…
Genetic Analysis AS offentliggör utfall i optionsinlösen (opens in a new tab)
Outcome TO2 options warrants The post Genetic Analysis AS offentliggör utfall i optionsinlösen appeared first on Genetic Analysis.…
Minutes from the Extraordinary General Meeting (opens in a new tab)
The post Minutes from the Extraordinary General Meeting appeared first on Genetic Analysis.…
Genetic Analysis AS: Minutes from the Extraordinary General Meeting (opens in a new tab)
Oslo, Norway, November 20, 2023 – Genetic Analysis AS (the “Company”, Ticker: GEAN) held an Extraordinary General Meeting today, November 20[th], at 13:00 hours (CET) on the Company’s premises in Ulvenveien 80, Oslo. Today’s extraordinary general meeting formally decided on the share capital increase. All items on the …
Presentation of GA-map® by Genetic Analysis sparks great interest at xMAP® Connect EMEA in Amsterdam (opens in a new tab)
OSLO, NORWAY, November 16, 2023: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today that the Company recently presented its proprietary microbiome testing platform GA-map® at xMAP® Connect EMEA, a conference by Luminex Corporation – a DiaSorin Company. The presentation was about how GA’s …
Topline Data of Investigator-Sponsored Study of VE303 to Treat Hepatic Encephalopathy (HE) Presented at The Liver Meeting 2023 (opens in a new tab)
CAMBRIDGE, MA, November 13, 2023 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced details of a late-breaker poster presentation summarizing the results of an investigator-sponsored, randomized, placebo-con…
Notice of Extraordinary General Meeting 2023 (opens in a new tab)
Notice is hereby served that an extraordinary general meeting in Genetic Analysis AS (the “Company”) will be held on Monday 20 November 2023 at 13:00 hours in the Company’s premises in Ulvenveien 80, Oslo. Shareholders are encouraged to submit a proxy with voting instructions prior to the general meeting, see Appendix …
Information avseende nyttjandeperiod av teckningsoptioner av serie TO 2 i Genetic Analysis AS (opens in a new tab)
The post Information avseende nyttjandeperiod av teckningsoptioner av serie TO 2 i Genetic Analysis AS appeared first on Genetic Analysis.…
Correction: Updated intended record date for the intended Subsequent Offering announced in press release, November 2, 2023 (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…
Subscriptions received in separate tranche of previously announced directed share issue (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…
Board member resigns at his request (opens in a new tab)
OSLO, NORWAY – November 2, 2023: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today that the board member Staffan Strömberg has resigned from the Board of Directors (“BoD”) at his request, due to high workload, with immediate effect. “I am unable to fully participate in the board work as …
Interim report January – September 2023 (opens in a new tab)
OSLO, NORWAY, November 2, 2023 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the third quarter and the first nine months of 2023. The interim report is available as an attached file to this release and on the Company’s website (www.genetic-analysis.com). Below is a summary of the…
Genetic Analysis announces placement of directed share issue of appr. NOK 10 mill, intention to conduct subsequent offering to shareholders, non-binding LoI for further investment, updated milestones (opens in a new tab)
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS R…
Genetic Analysis announces placement of directed share issue of appr. NOK 10 mill, intention to conduct subsequent offering to shareholders, non-binding letter of intent for further investment as well as updated milestones (opens in a new tab)
GA private placement letter of intent milestones The post Genetic Analysis announces placement of directed share issue of appr. NOK 10 mill, intention to conduct subsequent offering to shareholders, non-binding letter of intent for further investment as well as updated milestones appeared first on Genetic Analysis.…
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million (opens in a new tab)
Rapid growth of VOWST continues with more than 1,500 patient enrollment forms received since FDA approval Announces strategic restructuring to focus resources and investment on continued VOWST growth, completion of SER-155 Phase 1b study, and supporting longer-term business sustainability Reduction…
Seres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. EST (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Oct. 30, 2023– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will release third quarter 2023 financial results on Thursday, November 2, 2023 . Management will host a conference call with investors to…
Vedanta Biosciences to Host Investor Meetings at the Wells Fargo Virtual Private Biotech Symposium (opens in a new tab)
CAMBRIDGE, MA, October 25, 2023 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that management will host investor meetings at the Wells Fargo Virtual Private Biotech Symposium being held on Wednesday, No…